Spero Therapeutics, Inc. Segment Reporting Other Item Amount
Spero Therapeutics, Inc. (SPRO) reported Segment Reporting Other Item Amount of $3.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Notes › Segment Reporting
us-gaap:SegmentReportingOtherItemAmount · last filed 2026-08-12
- Spero Therapeutics, Inc. segment reporting other item amount for the quarter ending 2026-06-30 was $3.00K, a 96.20% decline year-over-year.
- Spero Therapeutics, Inc. segment reporting other item amount for the quarter ending 2026-03-31 was $1.00K, a 99.43% decline year-over-year.
- Spero Therapeutics, Inc. segment reporting other item amount for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- Spero Therapeutics, Inc. segment reporting other item amount for the quarter ending 2025-09-30 was $585.00K, a 2150.00% increase year-over-year.
- Spero Therapeutics, Inc. segment reporting other item amount for fiscal 2025 was $838.00K, a 2.57% increase from fiscal 2024.
- Spero Therapeutics, Inc. segment reporting other item amount for fiscal 2024 was $817.00K, a 84.64% decline from fiscal 2023.
- Spero Therapeutics, Inc. segment reporting other item amount for fiscal 2023 was $5.32M.
| Period end | Segment Reporting Other Item Amount 3 month | Segment Reporting Other Item Amount 6 month | Segment Reporting Other Item Amount 9 month | Segment Reporting Other Item Amount 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.00K 10-Q · filed 2026-08-12 | $4.00K 10-Q · filed 2026-08-12 | $4.00K derived: sum of 3 quarters · filed 2026-08-12 | $589.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $1.00K 10-Q · filed 2026-05-13 | $1.00K derived: sum of 2 quarters · filed 2026-05-13 | $586.00K derived: sum of 3 quarters · filed 2026-05-13 | $665.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $585.00K derived: sum of 2 quarters · filed 2026-03-26 | $664.00K derived: sum of 3 quarters · filed 2026-08-12 | $838.00K 10-K · filed 2026-03-26 |
| 2025-09-30 | $585.00K 10-Q · filed 2025-11-13 | $664.00K derived: sum of 2 quarters · filed 2026-08-12 | $838.00K 10-Q · filed 2025-11-13 | $1.62M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $79.00K 10-Q · filed 2026-08-12 | $253.00K 10-Q · filed 2026-08-12 | $1.03M derived: sum of 3 quarters · filed 2026-08-12 | $1.06M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $174.00K 10-Q · filed 2026-05-13 | $952.00K derived: sum of 2 quarters · filed 2026-05-13 | $978.00K derived: sum of 3 quarters · filed 2026-05-13 | $977.00K derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $778.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $804.00K derived: sum of 2 quarters · filed 2026-03-26 | $803.00K derived: sum of 3 quarters · filed 2026-03-26 | $817.00K 10-K · filed 2026-03-26 |
| 2024-09-30 | $26.00K 10-Q · filed 2025-11-13 | $25.00K derived: sum of 2 quarters · filed 2025-11-13 | $39.00K 10-Q · filed 2025-11-13 | |
| 2024-06-30 | -$1.00K 10-Q · filed 2025-08-12 | $13.00K 10-Q · filed 2025-08-12 | ||
| 2024-03-31 | $14.00K 10-Q · filed 2025-05-13 | |||
| 2023-12-31 | $5.32M 10-K · filed 2025-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 |